UniQure Jumps 78% as FDA Accepts Phase 1/2 Data for AMT-130 BLA

For biotech and pharma professionals, the FDA’s reversal from requiring additional data to accepting Phase 1/2 results for a BLA underscores the strength of AMT-130’s clinical dossier and its potential to set a precedent for gene therapy approvals in neurodegenerative disorders. The requirement for a concurrent-control confirmatory study, rather than sham, reflects a pragmatic regulatory approach that balances speed with evidence generation.

On June 17, 2026, UniQure’s stock roared 78.44% higher to $48.16, its largest single-day gain, after the U.S. Food and Drug Administration (FDA) reversed its earlier stance and accepted existing clinical data from the Phase 1/2 study of AMT-130, the company’s gene therapy for Huntington’s disease (HD). This pivotal decision removes a significant regulatory obstacle and puts the therapy on a direct path to a Biologics License Application (BLA) submission, scheduled for the third quarter of 2026. For a disease that currently lacks any disease-modifying treatment, the progression of AMT-130 toward potential approval represents a watershed moment for both patients and the broader gene therapy field.

“

On June 17, 2026, UniQure’s stock roared 78.44% higher to $48.16, its largest single-day gain, after the U.S.

Huntington’s disease is a fatal neurodegenerative disorder caused by a single genetic mutation that leads to progressive motor, cognitive, and psychiatric decline. Existing treatments are purely symptomatic, leaving a vast unmet medical need. AMT-130 delivers a microRNA designed to silence the huntingtin gene, aiming to halt or slow the disease’s progression. In early clinical trials, the therapy demonstrated promising biomarker and clinical endpoint improvements, earning it an FDA Regenerative Medicine Advanced Therapy (RMAT) designation—the first such designation for HD—along with breakthrough and fast-track statuses. These designations underscored the therapy’s potential and gave UniQure access to accelerated development and review pathways.

The FDA’s decision to accept the existing data analysis, effectively walking back its earlier request for additional data, surprised the market and signaled a significant confidence boost in the therapy’s data package. UniQure CEO Matt Kapusta highlighted that the FDA acknowledged the data’s strength and agreed it could support a near-term BLA submission. However, the agency also introduced a new requirement: an alignment meeting to finalize the design of a confirmatory study, specifically urging the use of a concurrent control arm on standard-of-care therapy rather than a sham procedure. This nuance is critical; it reflects the FDA’s pragmatic balancing act between speeding access to a badly needed therapy and ensuring robust confirmatory evidence in a post-marketing setting.

The market’s reaction, a 78% surge, underscores how heavily UniQure’s valuation hinged on this regulatory clarity. With a $48.16 closing price, the company’s market capitalization swelled, potentially easing future financing needs. The next key catalyst is the BLA submission, which the company expects in Q3 2026, followed by the alignment meeting on the confirmatory study. If successful, AMT-130 could become the first gene therapy approved for a neurodegenerative disorder, opening a new frontier for similar approaches in Alzheimer’s, Parkinson’s, and ALS.